Edition:
India

Inovio Pharmaceuticals Inc (INO.OQ)

INO.OQ on NASDAQ Stock Exchange Global Select Market

4.47USD
1:30am IST
Change (% chg)

$0.01 (+0.22%)
Prev Close
$4.46
Open
$4.50
Day's High
$4.62
Day's Low
$4.45
Volume
175,978
Avg. Vol
274,529
52-wk High
$9.85
52-wk Low
$3.77

Chart for

About

Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery... (more)

Overall

Beta: 2.96
Market Cap(Mil.): $600.01
Shares Outstanding(Mil.): 90.23
Dividend: --
Yield (%): --

Financials

BRIEF-Inovio Awarded Up To $56 Million From Cepi To Advance Dna Vaccines Against Lassa Fever And Mers

* INOVIO AWARDED UP TO $56 MILLION FROM CEPI TO ADVANCE DNA VACCINES AGAINST LASSA FEVER AND MERS

11 Apr 2018

BRIEF-Inovio Closes License And Collaboration Agreement With ApolloBio To Develop And Commercialize VGX-3100 In Greater China

* INOVIO CLOSES LICENSE AND COLLABORATION AGREEMENT WITH APOLLOBIO TO DEVELOP AND COMMERCIALIZE VGX-3100 IN GREATER CHINA

20 Mar 2018

BRIEF-Inovio Pharmaceuticals Reports Qtrly ‍Net Loss Attributable To Stockholders Of $0.24 Per Basic Share​

* INOVIO PHARMACEUTICALS REPORTS 2017 FOURTH QUARTER AND YEAR END FINANCIAL RESULTS

15 Mar 2018

BRIEF-Inovio's DNA Immunotherapy Demonstrates Immune Response Results Key In Treating Chronic Hepatitis B Infection

* INOVIO'S DNA IMMUNOTHERAPY DEMONSTRATES IMMUNE RESPONSE RESULTS KEY IN TREATING CHRONIC HEPATITIS B INFECTION Source text for Eikon: Further company coverage:

14 Mar 2018

BRIEF-Inovio Pharmaceuticals, Parker Institute For Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy Combinations

* INOVIO PHARMACEUTICALS AND THE PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY ESTABLISH CLINICAL DEVELOPMENT COLLABORATION TO EVALUATE NOVEL CANCER IMMUNOTHERAPY COMBINATIONS

09 Jan 2018

BRIEF-Inovio Receives Milestone Payment From Medimmune

* INOVIO RECEIVES MILESTONE PAYMENT FROM MEDIMMUNE AS MEDI0457 AND CHECKPOINT INHIBITOR COMBINATION TRIAL IN HEAD AND NECK SQUAMOUS CELL CANCER ADVANCES TO PHASE 2 Source text for Eikon: Further company coverage:

08 Jan 2018

BRIEF-Inovio Enters License, Collaboration Agreement With Apollobio To Develop, Commercialize VGX-3100 In Greater China

* INOVIO ENTERS LICENSE AND COLLABORATION AGREEMENT WITH APOLLOBIO TO DEVELOP AND COMMERCIALIZE VGX-3100 IN GREATER CHINA

02 Jan 2018

BRIEF-‍Inovio Pharma Cancer Vaccine Shows Promise In Preclinical Trial

* ‍INOVIO PHARMACEUTICALS SYNCON TERT CANCER IMMUNOTHERAPY COMBINED WITH CHECKPOINT INHIBITOR SYNERGISTICALLY SHRINKS TUMOR,IMPROVES SURVIVAL IN PRECLINICAL TUMOR MODEL​ Source text for Eikon: Further company coverage:

27 Nov 2017

BRIEF-Inovio pharmaceuticals reports 2017 third quarter financial results

* Inovio Pharmaceuticals reports 2017 third quarter financial results

09 Nov 2017

BRIEF-Inovio Pharma says ‍on Oct 30, Apollobio board approved agreements of license & collaboration agreement with co which was announced on July 14

* Inovio Pharmaceuticals says ‍on Oct 30, Apollobio board approved agreements of license & collaboration agreement with co which was announced on July 14

02 Nov 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $128.01 +1.25
Novartis AG (NOVN.S) CHF76.10 --
Pfizer Inc. (PFE.N) $36.85 +0.17
Merck & Co., Inc. (MRK.N) $59.41 -0.22
Sanofi SA (SASY.PA) €66.31 --
GlaxoSmithKline plc (GSK.L) 1,436.80 --
AstraZeneca plc (AZN.L) 4,992.00 --

Earnings vs. Estimates